Highlights MBX Biosciences, Inc.

Equities

MBX

US55287L1017

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:13:07 2026-04-15 pm EDT			5-day change	1st Jan Change
33.18 ^USD	+1.11%		+3.90%	+4.30%

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Highlights

Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Mar. 12	MBX Biosciences Q4 Net Loss Widens; Expects Cash Runway Into 2029	MT
Mar. 12	Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss	MT
Mar. 10	MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer	CI
Mar. 09	MBX Biosciences Announces Phase 3 Development Plan For Once-Weekly Canvuparatide For Hypoparathyroidism	CI
Jan. 11	Mbx Biosciences says phase 3 trial of canvuparatide to start in Q3 2026	RE
Nov. 06	MBX Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-25	MBX Biosciences Prices Upsized $200 Million Common Stock Offering	MT
25-09-22	MBX Biosciences Files for Public Offering of 10 Million Shares	MT
25-09-22	MBX Biosciences announces proposed public offering	RE
25-09-22	MBX Biosciences, Inc. Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responsonder Rate at 12 Weeks;79% Responder Rate at 6 Months in Open-Label Extension	CI
25-09-22	MBX Biosciences, Inc. Plans to Initiate A Phase 3 Clinical Trial of Once-Weekly Canvuparatide in 2026	CI
25-09-04	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity	CI
25-08-07	MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-07	MBX Biosciences reports second quarter 2025 financial results and recent corporate highlights	RE
25-06-16	MBX Biosciences, Inc. Announces IND Submission of MBX 4291, its Long-Acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity	CI
25-06-10	MBX Biosciences, Inc. to Present At the American Diabetes Association 85Th Scientific Sessions	CI
25-05-12	MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-17	MBX Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-17	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-12	Top Premarket Decliners	MT
25-03-03	MBX Biosciences, Inc. Completes Enrollment in Phase 2 Avail?? Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism	CI
25-01-07	MBX Biosciences, Inc. Announces Positive Phase 1 Topline Data for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia	CI
24-12-02	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism	CI
24-11-18	Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia	CI